Evidence map›Paper›PMID 42437850›Full record

ReviewCardiology and therapy2026

Defining Heart Failure Endpoint in ATTR Amyloidosis Clinical Trials: Time for an Update?

Diona Gjermeni, Kevin M Alexander, James L Januzzi, Kenneth W Mahaffey

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardiology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Diona GjermeniStanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, 3180 Porter Drive, Palo Alto, CA, 94304, USA. gjermeni@stanford.edu.ORCID http://orcid.org/0000-0003-1711-3901
Kevin M AlexanderStanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, 3180 Porter Drive, Palo Alto, CA, 94304, USA.
James L JanuzziBaim Institute for Clinical Research, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Kenneth W MahaffeyStanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, 3180 Porter Drive, Palo Alto, CA, 94304, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This viewpoint highlights the critical need for a standardized definition of heart failure (HF) endpoints in clinical trials specific to transthyretin cardiac amyloidosis (ATTR-CA). Current endpoint definitions vary significantly across standard HF and amyloidosis trials. The objective of this viewpoint is to support clinical trialists by providing practical considerations on how to better define HF events when designing amyloidosis clinical trials, as well as during the adjudication process. We suggest defining HF events based on three major components: acute hospitalizations or inpatient visits for HF, urgent outpatient HF visits, and recurrent outpatient visits. By refining these definitions, we aim to create a framework that accurately reflects the complexities of HF in amyloidosis and promotes consistency in endpoint definitions or HF event adjudication.

Indexed as

Cardiac amyloidosisClinical trialsHeart failure

Identifiers

PMID42437850
PMCPMC13542036

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.